The prognostic significance of ERBB1 mRNA amplification was confirmed for the high-risk non-GCB (ABC-type + unclassified) type as well as advanced-stage DLBCL patients (Figure 7 and Figure 8). This evidence concerns the gene EGFR and diffuse large B-cell lymphoma.